by: Parent Project Muscular DystrophySolid Biosciences joined PPMD for a community webinar on December 6, 2023 to provide an overview of INSPIRE DUCHENNE, a first-in-human clinical study evaluating SGT-003, a next-generation microdystrophin gene therapy candidate for the treatment of Duchenne muscular dystrophy. During the webinar, members of Solid’s Clinical and Patient Advocacy teams shared details about SGT-003 and the INSPIRE DUCHENNE study.
